RCEL Form 4: Director Robert McNamara acquires 10,000 shares

Rhea-AI Filing Summary

Avita Medical, Inc. (RCEL) director Robert McNamara reported a purchase of 10,000 shares of the company's common stock on 08/19/2025 at a price of $5.00 per share, bringing his beneficial ownership to 76,771 shares. The Form 4 was signed by power of attorney on 08/20/2025.

Positive

• Director purchase documented: 10,000 shares acquired on 08/19/2025 at $5.00 per share
• Disclosure completeness: Form 4 reports beneficial ownership after the transaction (76,771 shares) and includes signature via power of attorney dated 08/20/2025

Negative

• None.

Insights

Financial Analyst

TL;DR: Director purchase of 10,000 shares recorded; holdings now 76,771 shares.

The filing documents a straightforward, non-derivative purchase by a company director: 10,000 shares acquired at $5.00 on 08/19/2025, increasing reported beneficial ownership to 76,771 shares. The Form 4 was executed by power of attorney on 08/20/2025. The disclosure is complete for the transaction types reported and contains no derivative or disposition activity.

Corporate Governance Expert

TL;DR: Proper Section 16 reporting for an insider purchase is filed and signed by POA.

The document identifies the reporting person as a director and marks the filing as by one reporting person. Transaction code P indicates a purchase and the Form 4 includes the required signature block executed by a named power of attorney. No amendments or additional transactions are reported on this form.

Insider Trade Summary

Net Buyer: 10,000 shares ($50,000)

Net Buy 1 txn

Insider McNamara Robert

Role Director

Bought 10,000 shs ($50K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,000	$5.00	$50K

Holdings After Transaction: Common Stock — 76,771 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McNamara Robert

(Last) (First) (Middle)

C/O AVITA MEDICAL 28159 AVENUE STANFORD

SUITE 220

(Street)

VALENCIA CA 91355

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AVITA Medical, Inc. [ RCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2025		P		10,000	A	$5	76,771	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Nicole Kelsey, by power of attorney	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who reported the transaction on Form 4 for RCEL?

The reporting person is Robert McNamara, reported as a director of Avita Medical, Inc.

What transaction was reported for RCEL on this Form 4?

A purchase of 10,000 shares of common stock on 08/19/2025 at $5.00 per share.

How many shares did the reporting person own after the transaction?

The reporting person beneficially owned 76,771 shares following the reported purchase.

When was the Form 4 signed and by whom?

The form was signed by Nicole Kelsey, by power of attorney on 08/20/2025.

Does the Form 4 report any derivative transactions or dispositions?

No. The filing reports a non-derivative purchase only; Table II shows no derivative securities activity.